A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 153,37 (-16,19%). A mediana é € 146,57 (-19,91%).
| Comprar |
8 |
| Manter |
3 |
| Vender |
0 |
Notícias Ir para o feed de notícias
Cidara to be acquired by Merck for $9.2 billion as shares jump 105%
Cidara entered a definitive agreement under which Merck will acquire the company for $221.50 per share, valuing the deal at about $9.2 billion and expected to close in Q1 2026. Shares rose as high as $218.85 and finished the day up 105%. The deal follows FDA fast track designation for Cidara’s CD388, a Phase 3 candidate to prevent influenza in higher-risk patients. » Mais em finance.yahoo.com
Cidara Therapeutics to be acquired by Merck for $9.2 billion as shares surge 105%
Cidara Therapeutics entered a definitive agreement to be acquired by Merck for $9.2 billion, with Merck’s subsidiary offering $221.50 per share and the transaction expected to close in Q1 2026. The deal follows FDA fast track designation for Cidara’s influenza prevention candidate CD388, which is in a Phase 3 trial for high‑risk patients. Shares spiked to a near-decade high on the news, finishing the day up about 105%. » Mais em finance.yahoo.com
Merck & Co. close to acquiring Cidara Therapeutics
Merck & Co. is reportedly in short-term talks to buy Cidara Therapeutics, a developer of a long-acting antibody drug to protect against influenza. Completion of the deal could value Cidara at around $3.3 billion in market capitalization including a premium. Amid the bidding battle, Cidara’s stock rose about 50% in after-hours trading. » Mais em deraktionaer.de
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2025 | |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | -38,35 mi | - |
| Ganho líquido | -70,93 mi | - |
| EBITDA | -70,9 mi | - |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 4,84 bi |
Número de ações | 25,36 mi |
Máximo/mínimo de 52 semanas | € 190,91 - € 13,12 |
| Dividendos | Não |
Beta | 1,53 |
PER (PE Ratio) | -34,54 |
PEG (PEG Ratio) | -1,17 |
P/VC (PB Ratio) | 8,15 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
Cidara Therapeutics, Inc. ist ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von lang wirkenden Antiinfektiva für die Behandlung und Prävention von Infektionskrankheiten und Onkologie in den Vereinigten Staaten konzentriert. Der führende Produktkandidat des Unternehmens ist Rezafunginacetat, ein neuartiges Molekül aus der Klasse der Echinocandin-Antimykotika zur Behandlung und Vorbeugung von invasiven Pilzinfektionen, einschließlich Candidämie und invasiver Candidose, d.h. Pilzinfektionen, die mit einer hohen Sterblichkeitsrate verbunden sind. Darüber hinaus entwickelt das Unternehmen mit seiner Cloudbreak-Plattform Konjugate zur Vorbeugung und Behandlung von Grippe und anderen Virusinfektionen wie RSV, HIV und den SARS-CoV-2-Stämmen, die COVID-19 verursachen. Das Unternehmen war früher als K2 Therapeutics, Inc. bekannt und änderte im Juli 2014 seinen Namen in Cidara Therapeutics, Inc. Cidara Therapeutics, Inc. wurde im Jahr 2012 gegründet und hat seinen Sitz in San Diego, Kalifornien.
| Nome | Cidara Therapeutics |
| CEO | Jeffrey L. Stein |
| Sede | San Diego,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Biotecnologia |
| Entrada em bolsa | 15/04/2015 |
| Colaboradores | 38 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | CDTX |
